Ventilation heterogeneity predicts asthma control in adults following inhaled corticosteroid dose titration - 27/06/12
, Gregory G. King, MBChB, PhD a, b, c, d, Nathan J. Brown, PhD a, b, c, Matthew J. Peters, MD b, e, Norbert Berend, MD a, b, c, Cheryl M. Salome, PhD a, b, c
Corresponding author: Claude S. Farah, MBBS, Airway Physiology Group, Woolcock Institute of Medical Research, PO Box M77, Missenden Rd, Glebe, NSW 2050, Australia.Abstract |
Background |
Asthma guidelines recommend inhaled corticosteroid (ICS) dose titration for patients on the basis of an assessment of current asthma control. However, the physiological determinants of asthma symptom control are poorly understood and spirometry is a poor predictor of symptomatic response.
Objective |
To determine the role of small airway measurements in predicting the symptom response following ICS dose titration.
Methods |
Adult asthmatic patients had the Asthma Control Questionnaire (ACQ) scores and lung function measured at baseline and after 8 weeks. Tests included spirometry, plethysmography, sputum cell count, exhaled nitric oxide, airway hyperresponsiveness to mannitol, respiratory system mechanics using the forced oscillation technique, and ventilation heterogeneity using the multiple breath nitrogen washout. The parameters ventilation heterogeneity in convection-dependent airways and ventilation heterogeneity in diffusion-dependent airways were derived as measures of ventilation heterogeneity in the small airways. The dose of ICS was doubled if the ACQ score was greater than or equal to 1.5 (uptitration) and quartered if the ACQ score was less than 1.5 (downtitration). The relationships between baseline physiological parameters and the change in the symptom-only 5-item ACQ (deltaACQ-5) were examined by using Spearman correlations, forward stepwise linear regressions, and receiver operator curve analyses.
Results |
ICS dose uptitration (n = 20) improved ACQ-5 scores (1.76 to 1.16; P = .04). Baseline fraction of exhaled nitric oxide (r = −0.55; P = .01) and ventilation heterogeneity in convection-dependent airways (r = −0.64; P = .002) correlated with deltaACQ-5, but ventilation heterogeneity in convection-dependent airways was the only independent predictor (r2 = 0.34; P = 0.007). ICS dose downtitration (n = 41) worsened ACQ-5 scores (0.46 to 0.80; P < .001), with 29% of the patients having a deltaACQ-5 of greater than 0.5. Only baseline ventilation heterogeneity in diffusion-dependent airways correlated with deltaACQ-5 (r = 0.40; P = .009) and identified subjects with deltaACQ-5 of greater than 0.5 (receiver operator curve area under the curve = 0.78; P = .0003).
Conclusions |
Ventilation heterogeneity predicts symptomatic responses to ICS dose titration. Worse small airways function predicts symptomatic improvement to ICS dose uptitration and loss of symptom control during downtitration.
Le texte complet de cet article est disponible en PDF.Key words : Ventilation heterogeneity, small airways, asthma control, symptoms, inflammation, asthma, multiple breath nitrogen washout, forced oscillation technique
Abbreviations used : ACQ, ACQ-5, AHR, Feno, FOT, FVC, ICS, LABA, MBNW, Sacin, Scond
Plan
| This study was supported by a research grant from the Cooperative Research Centre for Asthma and Airways. Pharmaxis Ltd provided the mannitol kits for the bronchial challenge. |
|
| Disclosure of potential conflict of interest: C. S. Farah has received honoraria from AstraZeneca, GlaxoSmithKline, Novartis, and Pfizer. G. G. King has received research support from the Cooperative Research Centre for Asthma and Airways, National Health and Medical Research Council, and GlaxoSmithKline and has provided legal consultation/expert witness testimony for GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim. C. M. Salome has received research support from the Cooperative Research Centre for Asthma and Airways, National Health and Medical Research Council of Australia, and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 130 - N° 1
P. 61-68 - juillet 2012 Retour au numéro
Article précédent
- Corticosteroid use and bone mineral accretion in children with asthma: Effect modification by vitamin D
- Sze Man Tse, H. William Kelly, Augusto A. Litonjua, Mark L. Van Natta, Scott T. Weiss, Kelan G. Tantisira, Childhood Asthma Management Program Research Group
- Methacholine challenge test: Diagnostic characteristics in asthmatic patients receiving controller medications
- Kaharu Sumino, Elizabeth A. Sugar, Charles G. Irvin, David A. Kaminsky, Dave Shade, Christine Y. Wei, Janet T. Holbrook, Robert A. Wise, Mario Castro, American Lung Association Asthma Clinical Research Centers ∗
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?